USC’s Keck School of Medicine partners with StemCardia to advance heart failure treatment

FHS
October 8, 2024
11:28 pm

The Keck School of Medicine of USC has launched a strategic collaboration with StemCardia, a biotechnology company, founded by a Keck School of Medicine faculty member, that develops cellular and genetic therapies to address heart failure.

Almirall’s Ebglyss recommended by NICE for NHS atopic dermatitis patients

Almirall S.A., a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss

July 13, 2024

In surprise move, FDA delays decision on Lilly’s Alzheimer’s drug, will convene advisory committee

The FDA has pushed back its decision on Eli Lilly’s highly anticipated Alzheimer’s drug donanemab and plans to convene an advisory committee to review it,

March 9, 2024

Psilera Receives Positive Preclinical in Vivo Data for Frontotemporal Dementia (FTD) Candidate, PSIL-006 | Psychedelic Invest

Bolstered by the latest preclinical data, Psilera is poised to advance their lead asset, PSIL-006, towards first-in-human studies for Frontotemporal Dementia (FTD). TAMPA, Fla., Aug.

August 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.